Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Change in Accured Expenses (2023 - 2024)

Sagimet Biosciences (SGMT) has 2 years of Change in Accured Expenses data on record, last reported at $444000.0 in Q4 2024.

  • For Q4 2024, Change in Accured Expenses rose 38.75% year-over-year to $444000.0; the TTM value through Dec 2024 reached -$907000.0, down 855.83%, while the annual FY2025 figure was $929000.0, 202.43% up from the prior year.
  • Change in Accured Expenses reached $444000.0 in Q4 2024 per SGMT's latest filing, up from -$1.7 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $1.4 million in Q3 2023 and bottomed at -$1.7 million in Q3 2024.